NEUVENGE Trademark

Trademark Overview

On Thursday, May 8, 2008, a trademark application was filed for NEUVENGE with the United States Patent and Trademark Office. The USPTO has given the NEUVENGE trademark a serial number of 77469775. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 2, 2012. This trademark is owned by Dendreon Corporation. The NEUVENGE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the treatment of cancer, infectious and autoimmune diseases
neuvenge

General Information

Serial Number77469775
Word MarkNEUVENGE
Filing DateThursday, May 8, 2008
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 2, 2012
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 10, 2009

Trademark Statements

Goods and ServicesPharmaceuticals for use in the treatment of cancer, infectious and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 13, 2008
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDendreon Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98121
Party NameDendreon Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98121

Trademark Events

Event DateEvent Description
Monday, July 2, 2012ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, July 2, 2012ABANDONMENT - NO USE STATEMENT FILED
Friday, September 30, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 29, 2011EXTENSION 5 GRANTED
Monday, September 26, 2011EXTENSION 5 FILED
Monday, September 26, 2011TEAS EXTENSION RECEIVED
Wednesday, May 4, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 3, 2011EXTENSION 4 GRANTED
Monday, April 25, 2011EXTENSION 4 FILED
Monday, April 25, 2011TEAS EXTENSION RECEIVED
Tuesday, September 28, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 27, 2010EXTENSION 3 GRANTED
Tuesday, September 21, 2010EXTENSION 3 FILED
Tuesday, September 21, 2010TEAS EXTENSION RECEIVED
Saturday, March 20, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 19, 2010EXTENSION 2 GRANTED
Thursday, March 18, 2010EXTENSION 2 FILED
Thursday, March 18, 2010TEAS EXTENSION RECEIVED
Monday, September 14, 2009EXTENSION 1 GRANTED
Friday, September 11, 2009EXTENSION 1 FILED
Friday, September 11, 2009TEAS EXTENSION RECEIVED
Monday, August 17, 2009APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, August 17, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 21, 2009PAPER RECEIVED
Tuesday, June 2, 2009NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 10, 2009PUBLISHED FOR OPPOSITION
Wednesday, February 18, 2009NOTICE OF PUBLICATION
Thursday, February 5, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, February 4, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 29, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 29, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 29, 2009ASSIGNED TO LIE
Monday, January 26, 2009TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 18, 2008NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 18, 2008NON-FINAL ACTION E-MAILED
Monday, August 18, 2008NON-FINAL ACTION WRITTEN
Friday, August 15, 2008ASSIGNED TO EXAMINER
Tuesday, May 13, 2008NEW APPLICATION ENTERED IN TRAM

Related Keywords

neuvenge autoimmune diseases infectious cancer treatment pharmaceuticals